Drug Profile
Acetylcysteine/pentoxifylline
Alternative Names: Acetylcysteine/oxpentifylline; Oxpentifylline/acetylcysteine; Pentoxifylline/acetylcysteine; PTL-202Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Pacific Therapeutics
- Class Antifibrotics; Reducing agents; Small molecules; Sulfur amino acids; Xanthines
- Mechanism of Action Antioxidants; Cytokine inhibitors; Free radical scavengers; Phosphoric diester hydrolase inhibitors; Platelet aggregation inhibitors; Transforming growth factor beta inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in India (PO, Tablet)
- 08 May 2014 Acetylcysteine/pentoxifylline is still in phase I trials for Pulmonary fibrosis
- 04 Feb 2014 Pacific Therapeutics terminates its technology licence with Dalhousie University in Canada